医学
多塔
阶段(地层学)
肿瘤科
肺癌
核医学
螯合作用
有机化学
化学
古生物学
生物
作者
S. Liu,D. Planchard,K. Herrmann,A. D'Amelio,I. Folitar,L. Paz Ares
标识
DOI:10.1016/j.jtho.2022.07.955
摘要
New therapeutic agents are desperately needed for small cell lung cancer (SCLC), a high-grade, poorly differentiated neuroendocrine carcinoma of the lung, that often presents at an extensive stage (ES), and has high mortality rates. Response to current standard of care (SOC) is generally short-lived with most patients experiencing disease progression and a poor prognosis. Up to half of SCLC tumors express somatostatin receptors (SSTR). [177Lu]Lu-DOTA-TATE, a radioligand therapy, selectively targets SSTRs and has demonstrated a significant improvement in progression-free survival (PFS) and prolongation of overall survival (OS) in patients with SSTR-positive midgut neuroendocrine tumors.
科研通智能强力驱动
Strongly Powered by AbleSci AI